Biotech & AI drug discoverySTAT — Biotech

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

According to STAT, detailed data confirm that a personalized mRNA cancer vaccine from Moderna and Merck met key endpoints in a melanoma trial. The companies reported the vaccine reduced the risk of disease recurrence in melanoma patients by 42% compared with standard treatment.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-22T19:03:31+00:00

Published here2026-10-22T19:22:29+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/

Original headline

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.